

IncreaseNET and EU-Innovation Network 2026 Innovation & Competitiveness Summit: Strengthening Europe's Ecosystem

AGENDA

15 October 2026

8:30 – 8:50 **Registration**

Welcome Address

9:00 – 9:30

- *Catherine Paugam-Burtz* (Head of ANSM)
 - *Momir Radulović* (Head of JAZMP)
 - *Emmanuel Cormier* (Head of Regulatory Science and Innovation, EMA)
-

Session 1: Setting the scene

European competitiveness

- *Lilia Luchianov* (Policy Officer, European Commission)

Europe's Health Innovation Ecosystem

- *Falk Ehmann* (EU IN co-chair, Head of innovation and development accelerator, EMA)

9:30 – 10:20

IncreaseNET Current State of Play

- *Luka Kosec* (Coordinator of IncreaseNET, JAZMP)

Q&A

This session will set the scene for the conference by presenting its objectives, placing innovation support within the broader context of European competitiveness introducing transversal topics relevant to the evolving European regulatory landscape.

10:20 – 10:50 **Coffee break**

Session 2: Overview of Clinical Trials in an EU Member State

Introduction to clinical trials in France: actors, challenges and opportunities

- **Nina Hulin** (*Head of paediatrics, early clinical trials and therapeutic innovation department, ANSM*)

French funding mechanism & barriers to access

- **Vincent Vauchel** (*Deputy director, Research and innovation department, French Ministry of Health, DGRINES*)
- **Rosalie Maurisse** (*Head of Healthcare, BPI France, Public Investment Bank*)

10:50 – 12:00

Structure and support of oncology and rare diseases

- **Caroline Dreuillet** (*Head of Clinical research department, French National Cancer Institute (INCa)*)
- **Solange Roumengous** (*Team Leader, Partnerships and Expertise, French National Rare Disease Database (BNDMR)*)

Q&A

This session will provide an overview of the clinical trials in France with actors and set the scene for discussion on innovation support.

12:00 – 13:25 Lunch break

Keynote: *From Innovation to Patients: Support services for gene therapies, cell therapies and transplantation in France and Europe*

- **Marina Cavazzana** - *Professor of Paediatrics, Professor of Hematology Head of the Biotherapy Department, Hôpital Necker-Enfants Malades AP-HP*

Session 3: National and European service offering

Support for academia and SMEs: Experience & service offering

- **Frédéric Girard** (*President, France Biotech*)
- **Oriane Blanquie** (*Seconded national expert, EMA*)
- **Marco Fiorini** (*Executive Director, Artificial Intelligence and Cancer Program (FIAC)*)
- **Yoana Nuevo** (*EU Innovation Network co-chair, Head of National Innovation office & National Scientific Advice Unit, AEMPS*)

13h50 – 15:30

Scientific and regulatory advice across Europe

- **Paolo Foggi** (SAWP Chair, EMA)
- **Marianne Lunzer** (CTCG chair, AGES)

A French approach: Overview of supported projects

- **Charles Édouard Escurat** (General Director, French Health Innovation Agency (AIS))

Q&A

This session will explore support mechanisms available at National and European levels and how they should be complementary.

15:30 – 16:00 Coffee break

Round table discussion: Accessibility of the EMRN and readability of the landscape

- **Participants:** All conference participants
- **Discussion leads:** Emmanuel Cormier, Frédéric Girard, Guillaume Vaquer, Marina Cavazzana, Paolo Foggi

16:00 – 17:00

This round table will open a broader discussion on how to make EMRN support more accessible and easier to navigate.

17:00 – 17:15 General discussion and Wrap-up

All times are displayed in UTC+1 / Central European Time (CET).